Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 58

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis62Systemic lupus erythematosus61Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Sjogren's syndrome29Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis15Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+304

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Sjogren's syndrome

Not recruiting

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus

Not recruiting

Study on MK-6194 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mk-6194
  • Sponsor:Merck Sharp & Dohme LLC

Duchenne muscular dystrophy

Not recruiting

Study on the Safety and Efficacy of Viltolarsen for Boys with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Viltolarsen
  • Sponsor:Ns Pharma Inc.

Spinal muscular atrophy

Not recruiting

Study on the Effectiveness and Safety of Risdiplam for Children with Spinal Muscular Atrophy After Gene Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ewing's sarcoma

Not recruiting

Study of Abemaciclib, Irinotecan, and Temozolomide for Patients with Relapsed or Refractory Ewing's Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Rheumatoid arthritis

Not recruiting

Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Lupus nephritis+1

Not recruiting

Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Soft tissue sarcoma

Not recruiting

Study on Berzosertib and Gemcitabine for Adults with Advanced or Metastatic Soft-Tissue Leiomyosarcomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Berzosertib
  • Sponsor:Institut Bergonie

Back pain

Not recruiting

Study on Melatonin for Patients with Chronic Back Pain

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Melatonin
  • Sponsor:Odense University Hospital

Systemic lupus erythematosus

Not recruiting

Study of Belimumab for Children with Systemic Lupus Erythematosus (SLE)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Osteochondrodysplasia

Not recruiting

Study on the Effectiveness and Safety of Infigratinib for Children Aged 3 to 17 with Achondroplasia

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate25 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.